Sanofi (ETR:SNW)

Germany flag Germany · Delayed Price · Currency is EUR
86.95
-0.80 (-0.91%)
Jun 13, 2025, 5:35 PM CET
-2.65%
Market Cap 105.74B
Revenue (ttm) 45.17B
Net Income (ttm) 6.30B
Shares Out n/a
EPS (ttm) 5.04
PE Ratio 16.79
Forward PE 10.50
Dividend 3.92 (4.53%)
Ex-Dividend Date May 12, 2025
Volume 9,476
Average Volume 11,654
Open 86.93
Previous Close 87.75
Day's Range 85.75 - 87.16
52-Week Range 85.54 - 110.82
Beta 0.41
RSI 38.64
Earnings Date Jul 31, 2025

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange Deutsche Börse Xetra
Ticker Symbol SNW
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial Statements

News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to con...

23 hours ago - Accesswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY).  Such investors are advised to contact Daniel...

2 days ago - PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Dani...

4 days ago - GlobeNewsWire

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

4 days ago - Barrons

FDA approves Mercks RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

4 days ago - CNBC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact D...

4 days ago - Accesswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle...

6 days ago - PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Da...

7 days ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact D...

9 days ago - Accesswire

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries...

9 days ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to cont...

9 days ago - Accesswire

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPM...

10 days ago - Wallstreet:Online

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...

10 days ago - Business Wire

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-bo...

11 days ago - GlobeNewsWire

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Blueprint Medicines Corporation (BPMC)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Blueprint Medicines Cor...

11 days ago - Wallstreet:Online

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

11 days ago - CNBC Television

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciar...

11 days ago - GlobeNewsWire

Sanofi-Blueprint deal is a bullish signal about biotech M&A

The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. San...

11 days ago - Yahoo Finance

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

Kymera's KT-621 achieved rapid, deep STAT6 degradation and ... Full story available on Benzinga.com

11 days ago - Benzinga